Topiramate

Generic Name
Topiramate
Brand Names
Eprontia, Qsymia, Qudexy, Topamax, Trokendi
Drug Type
Small Molecule
Chemical Formula
C12H21NO8S
CAS Number
97240-79-4
Unique Ingredient Identifier
0H73WJJ391
Background

Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy in adults.
...

Indication

Topiramate is indicated for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associat...

Associated Conditions
Alcohol Dependency, Epilepsy, Primary Generalized Tonic-Clonic Seizures, Generalized Tonic-Clonic Seizures, Lennox-Gastaut Syndrome, Migraine, Moods Disorders, Partial-Onset Seizures, Seizures, Weight
Associated Therapies
Chronic Weight Management therapy, Weight Reduction

A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder

Phase 3
Completed
Conditions
First Posted Date
2002-05-03
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
338
Registration Number
NCT00035230

Topiramate in the Treatment of Sciatica

Phase 2
Completed
Conditions
First Posted Date
2001-03-01
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
Target Recruit Count
65
Registration Number
NCT00011804
Locations
🇺🇸

National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States

Study of the Pathogenesis of Rett Syndrome

Not Applicable
Completed
Conditions
First Posted Date
2000-02-25
Last Posted Date
2005-06-24
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Target Recruit Count
120
Registration Number
NCT00004807

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome

Phase 3
Completed
Conditions
First Posted Date
2000-02-25
Last Posted Date
2005-06-24
Lead Sponsor
National Center for Research Resources (NCRR)
Target Recruit Count
10
Registration Number
NCT00004776
© Copyright 2024. All Rights Reserved by MedPath